Evidence map›Paper›PMID 37773047›Full record

ArticleThe Journal of experimental medicine2023

Retinoic acid drives intestine-specific adaptation of effector ILC2s originating from distant sites.

Nikhat Shaikh, Alex Waterhölter, Ann-Christin Gnirck, Martina Becker, Virginia Adamiak, Lena Henneken, Malte Wunderlich, Wiebke Hartmann, Lara Linnemann, Tobias B Huber and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Nikhat ShaikhIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-0913-1766
Alex WaterhölterIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0009-0008-0464-0714
Ann-Christin GnirckIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0009-0009-8623-7132
Martina BeckerIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-7598-2964
Virginia AdamiakIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0009-0009-9783-9163
Lena HennekenIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0009-0002-3929-3798
Malte WunderlichIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-3881-2026
Wiebke HartmannHelminth Immunology Group, Bernhard Nocht Institute for Tropical Medicine , Hamburg, Germany.ORCID 0000-0002-4998-0586
Lara LinnemannHelminth Immunology Group, Bernhard Nocht Institute for Tropical Medicine , Hamburg, Germany.ORCID 0000-0003-4963-2888
Tobias B HuberIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-7175-5062
Christian F KrebsHamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf , Hamburg, Germany.ORCID 0000-0003-2739-5578
Ulf PanzerHamburg Center for Translational Immunology, University Medical Center Hamburg-Eppendorf , Hamburg, Germany.ORCID 0000-0001-9449-0722
Richard M LocksleyDepartment of Medicine, Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-5468-6867
Christoph WilhelmUnit for Immunopathology, Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, University of Bonn , Bonn, Germany.ORCID 0000-0002-9839-0291
Minka BreloerHelminth Immunology Group, Bernhard Nocht Institute for Tropical Medicine , Hamburg, Germany.ORCID 0000-0001-6199-4908
Jan-Eric TurnerIII. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-1677-5455
Universität Hamburg · DEBernhard Nocht Institute for Tropical Medicine · DEHoward Hughes Medical Institute · USUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adaptation of immune cells to tissue-specific microenvironments is a crucial process in homeostasis and inflammation. Here, we show that murine effector type 2 innate lymphoid cells (ILC2s) from various organs are equally effective in repopulating ILC2 niches in other anatomical locations where they adapt tissue-specific phenotypes of target organs. Single-cell transcriptomics of ILC2 populations revealed upregulation of retinoic acid (RA) signaling in ILC2s during adaptation to the small intestinal microenvironment, and RA signaling mediated reprogramming of kidney effector ILC2s toward the small intestinal phenotype in vitro and in vivo. Inhibition of intestinal ILC2 adaptation by blocking RA signaling impaired worm expulsion during Strongyloides ratti infection, indicating functional importance of ILC2 tissue imprinting. In conclusion, this study highlights that effector ILC2s retain the ability to adapt to changing tissue-specific microenvironments, enabling them to exert tissue-specific functions, such as promoting control of intestinal helminth infections.

Indexed as

Immunity, InnateTretinoinAnimalsCytokinesInflammationIntestinesLymphocytesMiceCytokinesTretinoin

Identifiers

PMID37773047
PMCPMC10541314
OpenAlexW4387168863

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.